Self-collected HPV testing for cervical screening: what the 2025-26 guidance now allows

Self-collection means the patient collects their own vaginal swab for high-risk HPV testing, in place of a cervical sample at speculum exam. The Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee (Wentzensen et al.) found self-collected vaginal specimens acceptable for primary HPV screening of asymptomatic, average-risk individuals ^[1]. The 2025 committee kept clinician-collected cervical specimens as the preferred option ^[1].

What do the current recommendations say?

• Consensus committee, April 2025: repeat testing in 3 years is recommended after an HPV-negative screen using a self-collected vaginal specimen ^[1].
• USPSTF draft, December 2024: the draft statement lists screening every 5 years with clinician- or patient-collected high-risk HPV primary screening for ages 30 to 65, and the update is in progress ^[2].
• ACS update, 2026 (online December 2025): the American Cancer Society (ACS) update endorses the consensus position for average-risk individuals aged 25 to 65 ^[3]. The 2026 ACS update recommends repeat testing in 3 years after a negative self-collected test and every 5 years after a negative clinician-collected test ^[3]. It limits self-collection to device and assay combinations approved by the US Food and Drug Administration (FDA) for HPV testing in a clinical setting or at home ^[3].
• After a positive result: the 2025 consensus committee recommends colposcopy for HPV 16 or 18 ^[1]. The 2025 consensus committee recommends clinician-collected cytology or dual stain for HPV 45, 33/58, 31, 52, 35/39/68, 51 or pooled other types with 16 and 18 negative ^[1]. The 2025 consensus committee recommends repeat HPV testing in 1 year for types 56/59/66 with no other carcinogenic type ^[1].
• Screening exit: the ACS update amends the 2020 ACS guideline to ask for negative primary HPV tests (co-testing is acceptable) at ages 60 and 65 ^[3]. The 2026 ACS update requires the last HPV test at age 65 or older before screening stops in average-risk patients ^[3].

How does self-collection compare with clinician collection?

In a 2018 BMJ meta-analysis of 56 accuracy studies, PCR-based HPV assays were as sensitive on self samples as on clinician samples for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) (pooled ratio 0.99, 95% CI 0.97 to 1.02), but signal-amplification assays were less sensitive on self samples (pooled ratio 0.85, 95% CI 0.80 to 0.89) ^[4]. The same meta-analysis found CIN2+ specificity 2% lower on self samples with PCR-based assays and 4% lower with signal-amplification assays ^[4]. A 2025 meta-analysis by Li and colleagues pooled 15 studies with 3,665 participants, all with abnormal screening results ^[5]. For lesions above CIN2, the 2025 meta-analysis by Li and colleagues reported vaginal self-sampling sensitivity of 98% (95% CI 96% to 99%) and specificity of 63% (95% CI 48% to 77%) ^[5]. These absolute values do not compare directly with the pooled ratios above.

Where is the evidence uncertain?

The 2025 consensus committee found minimal data on self-collected specimens for surveillance after abnormal results, colposcopy or treatment, and it lists clinician collection as preferred in those settings ^[1]. The 2026 ACS update by Perkins and colleagues notes that long-term, real-world effectiveness data for self-collection are limited and that most HPV-positive patients will need extra follow-up steps ^[3]. A 2025 commentary by Mayer and colleagues reports strong agreement between clinician and self-collected HPV results ^[6]. It states that clinician collection is still more sensitive for CIN2 or worse, a difference that in the 2018 meta-analysis depended on the assay ^[4][6]. In 2025, Mayer and colleagues said FDA approval covered self-collection in health care settings only ^[6]; the 2026 ACS update refers to device and assay combinations approved for a clinical setting or at home ^[3].

At the point of care: what to check

• Whether the specimen was self-collected, since the 2026 ACS update sets the repeat interval after a negative test at 3 years for self-collected and 5 years for clinician-collected specimens ^[3].
• Surveillance status, the setting in which the 2025 consensus committee lists clinician collection as preferred ^[1].
• The HPV genotype of a positive test, since the 2025 consensus committee ties types 16 or 18 to colposcopy, other listed carcinogenic types to clinician-collected cytology or dual stain, and types 56/59/66 alone to repeat testing at 1 year ^[1].
• Age and prior HPV results, since the 2026 ACS update asks for negative HPV tests at ages 60 and 65, with the last at age 65 or older ^[3].
• Whether the device and assay in use are FDA-approved for the setting, clinic or home, as the 2026 ACS update and Mayer and colleagues describe ^[3][6].